CXCL16-driven CD4 + T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors.
Journal for immunotherapy of cancer
Zhou Y, Chen P, Wang Z, Gui L, Zheng Z, Gao WQ, Ma B.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2026
Cancer Research
Immunology
No items found.
Key Finding
This differential effect correlated with changes in immune infiltrates. The context-dependent regulation of CXCL16 by MHC-I loss determines the immune landscape and tumor outcome, highlighting a potential therapeutic avenue for targeting MHC-I-deficient cancers.
Countstar Connection
Within the research, Countstar (model not specified) assessed cell numbers in the study's cell samples during quality assessment in the 2026 Journal for immunotherapy of cancer study.
